you, and call. Thank quarter today's results. everyone, attending for David. discuss fourth to you you, us thank Thank Eton's for everyone, afternoon, Good joining
of we items Xth growth product to XXXX share of continued expecting quarter today. the and million. some beyond, to momentum we XXXX in that that of and in was about company's sequential net the expect sales we will talking quarter growth $X.X only the and continue This our not do to due pleased are in streak be that through of income $X.X fourth positive XXXX in million with am to accelerate revenue straight I
year compared our at importantly and double We this to product revenue most XXXX. sales expect royalty to least
on start to would update I off, today organization. with like an commercial First our exciting
costs. dollars ALKINDI stages We of us sales to save you were promote XXXX, we force endocrinology SPRINKLE copromotion millions Tolmar SPRINKLE force into to leverage Pharmaceuticals. in of a allowed the of early many existing in Eton Tomar's pediatric agreement sales with agreement in large ALKINDI launch. This know, entered As and our
Due agreement force. sales the to we forecast us sales it our significant entered the this our to product at same roughly be projected year as going the amount commission for strong since expand our to XXXX, and cost would own Tolmar growth the in for was
we right we in our Tolmar control copromotion over was own there's contributions to agreement But cost So good sales we team. for ultimately having for our exit no no to exercised at thank their own the hired a January, partner product. and the and replacement them team. your complete
Eton completely the will deployed plan rare personnel and sales We financials will force that Now than sales even we house. us these staffed to is and when solely focused faster we force allow excited new benefits us allow control it in on XX believe Eton's justify, that highly with strategies, now structure to growing much The products the greater copromotion agreement. over it field. have incentive under sales are grow be the force exercise to experienced into fully decisions. been SPRINKLE were bring ALKINDI will specialists disease
these promoting both also Betaine, and is Carglumic boost In which force our addition, Acid should products sales both of new soon revenues.
already we've XXXX. incredible in fact, Acid Carglumic In patients our reps growth new sales on seen drive
our corporate products up about our Texas the fired opportunities very Meeting XXXX. National reps in from and entire the our returned just Sales sales I all in team and were the leadership for
strong is help can new for sales continued ALKINDI accelerate they and on product. adoption force We to Now a already patients updates. to quarter rate excited strong the are to see in with the in what specific growth Early see believe promising. our the are product do results very turning product. we treatment will what very
increase campaign force the to and engagement our to the marketing new with XXXX. a community efficiency in to consumer also further patient launched sales direct in adrenal plans we've enhancements, addition we In have
this growth performing. Carglumic extremely strong Acid and in we how with pleased Acid. are showed quarter is product the Carglumic
We to some continue Acid new believe steady patient very to a in success Betaine see off a with product. commercial product cadence We with notable be XXXX start patient good adds. the of the our replicated starts new and Carglumic can is
commercial Betaine As label the year a under reminder, preparing we product acquired and late are our now last to relaunch and infrastructure.
from eager same interest product. patients get The Carglumic as access received to from already to requests strong product that has are base seeing prescriber numerous physicians. we are Acid We and Eton's the directly
to the release, has inventory for it launch few manufactured labeled within we commercially been hope have available now weeks. is so next and and tested Our currently being
between believe I annually. sizes $XX million and million the $XX current Betaine market
revenue once ramped of with So expenses. minimal should dollars of many incremental SG&A provide millions up, Betaine
development to months. in with our the we the now of where have developments we the Turning fourth number exciting Starting had NDA FDA. response pipeline, injection, a to our of quarter, alcohol end dehydrated recent submitted at
FDA the of and review assigned date that us XX. accepted PDUFA a We June are to for see pleased
if a XX%. a working the We are the latest quickly now is IQVIA partner market $XX alcohol dehydrated commercialized is product our target as prepare launch it annually when Based as our so market approved. activities and possible be data, to and more share can the that would than of million be with on
SPRINKLE. we our our than insufficiency greater alongside progress rapidly us that We $XXX million in product patent plan have market the promote ET-XXX believe product advancing adrenal also candidate candidate. innovative that's ET-XXX will space. is opportunity ALKINDI We penetrate pediatric to This help the pending made
year. for been successfully batches later product have registration the we submit to and manufactured expect this NDA Our the
the and ET-XXX the launches plan product as combined and This Suffice it excess share happen and the expect that this XXXX we ALKINDI of have could details second to we annually we between half that get of we say, NDA submission. closer allow approval future. early more to to peak of will in and in in for SPRINKLE near $XX million will sales an
in very is our autoinjector, development for NDA important and which ready ZENEO adrenal next submission activities potential be Moving expects to engaged hydrocortisone treatment is on insufficiency year. community, actively for to ZENEO. partner
clinical During requested FDA significantly met our candidate regarding more ET-XXX. we We product. with also The justified the the studies that extensive early thought quarter, than for product FDA stage
we result, FDA term other on to focus while work our reach pathway. opportunities the a more try we to plan resources list scenes burdensome near As a behind agreement to on clinical
One of those the an is pediatric is we which for under rare development a very ET-XXX, announced acquisition near term this condition. opportunities ET-XXX endocrinology week. innovative of product
and opportunity excited it about unmet product for significant will are pediatric We this need a address patients. believe
the market repeatedly strategic prescriber have base product same bring that will minimal we us our need perfect company so a for it's for to this to be they is very fit It excited the incremental it with ALKINDI shortly. as been and Physicians have to to expressed SPRINKLE, hear working expenses.
We now. this development relatively a and year product NDA submission believe a quick with project be over straightforward possible from will the just
continue achievable are pipeline disease approved rare ET-XXX XX our and such provide finding we assets our us and more products by that company future I have market acquisitions that business is of immediate and stage products for to about Acid products Betaine. development additional will of goal hunt this for existing for on XXXX. revenue through prospects or products the development is rare believe My opportunities commercial the combination disease transactions. our We a recent optimistic contributions of as already could as to are late such Carglumic
market. put to on company, pace it were hope Eton investors how SPRINKLE, power for to an alcohol is in-house will is Acid, closing contribution. Given is them be deliver full to $XX ALKINDI revenue, all team of midyear growth have well supercharge we growth. million year A in is few this revenue this additional and meaningful me two that and to coming positioned I weeks to is Dehydrated on the launching to a already is this the it in one force going well clear in positioned of the Carglumic products year. That behind as sales earnings points, the massive launch provide now plus
position or business we at any to We that term pursue development this plans we the no and of value. still bolt-on on to plan, significant strong cash believe near create have dilution opportunities raise moment deliver can do kind a
excited this prospects company As such, for about goals Had financial more could two not I the be XXXX. year. our for
royalty First, least at year. sales and our revenue I double to from last product expect
dehydrated could Of than approved significantly it be be. expect more if is and alcohol launched that course, will as it we
is profitability some in breakout continuing here year. at throughout making year. goals reach at and This half on year. exciting you It's the for a And executing point these to vision expecting this year. update whole a forward in to I'm the I second support. on dedicated our of the Eton an progress our Secondly, look you XXXX. team your We to lastly, reality has thank
James, our to James? with turn to that, the Financial I over financials. discuss it And Chief Officer,
